Pages that link to "Q44710527"
Jump to navigation
Jump to search
The following pages link to Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. (Q44710527):
Displaying 20 items.
- Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML (Q33702150) (← links)
- Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. (Q33754603) (← links)
- DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group (Q34038587) (← links)
- MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group (Q34043467) (← links)
- The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study (Q34344493) (← links)
- Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: A report from the Children's Oncology Group (Q35190576) (← links)
- Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group (Q35430146) (← links)
- Clinical implications of FLT3 mutations in pediatric AML. (Q35848876) (← links)
- FLT3 internal tandem duplication in CD34 /CD33- precursors predicts poor outcome in acute myeloid leukemia (Q35849209) (← links)
- Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group (Q36407162) (← links)
- A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies (Q36988072) (← links)
- Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials (Q37324869) (← links)
- FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report (Q37454714) (← links)
- KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia (Q40100589) (← links)
- Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. (Q40392434) (← links)
- Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia (Q41866669) (← links)
- Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study (Q44907709) (← links)
- Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group (Q46120203) (← links)
- Recent publications in hematological oncology (Q80932791) (← links)
- Genomic variants of cytarabine sensitivity associated with treatment related mortality in pediatric AML: A report from the Children's Oncology Group (Q89982350) (← links)